icd 10 code for jak2 polycythemia vera

What is the ICD-10 code for JAK2?

jak2 (v617f) mutation, bloodCPT® (CDT codes and descriptions are copyright American Dental Association)86900ICD-10-CMC58Malignant neoplasm of placentaD61.81Pancytopenia123 more rows

What is the ICD-10 code for Polycythemia vera?

ICD-10 code D45 for Polycythemia vera is a medical classification as listed by WHO under the range - Neoplasms .

What is the ICD-10 code for secondary polycythemia?

ICD-10 code D75. 1 for Secondary polycythemia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .

What are the differential diagnosis of Polycythemia vera?

Differential diagnoses to consider include: Essential thrombocythemia. Chronic myelogenous leukemia. Agnogenic myeloid metaplasia.

What is Polycythaemia Vera?

Polycythemia vera (pol-e-sy-THEE-me-uh VEER-uh) is a type of blood cancer. It causes your bone marrow to make too many red blood cells. These excess cells thicken your blood, slowing its flow, which may cause serious problems, such as blood clots.

What is secondary polycythemia?

Secondary polycythemia is defined as an absolute increase in red blood cell mass that is caused by enhanced stimulation of red blood cell production. In contrast, polycythemia vera is characterized by bone marrow with an inherent increased proliferative activity.

What is the treatment for Polycythemia vera?

The most common treatment for polychythemia vera is having frequent blood withdrawals, using a needle in a vein (phlebotomy). It's the same procedure used for donating blood. This decreases your blood volume and reduces the number of excess blood cells.

Is polycythemia a disease?

Key points about polycythemia vera Polycythemia vera is a rare blood disorder in which there is an increase in all blood cells, particularly red blood cells. The increase in blood cells makes the blood thicker.

What is secondary Erythrocytosis?

Secondary polycythemia, also known as secondary erythrocytosis or secondary erythrocythemia, is a rare condition in which your body produces an excess amount of red blood cells. This overproduction of red blood cells thickens your blood.

Does secondary polycythemia have JAK2 mutation?

A study conducted James et al. [5] found that the JAK2 V617F mutation is strongly associated with PV but is not found in secondary polycythemia patients.

Is polycythemia and polycythemia vera the same?

Polycythemia, also called erythrocytosis, refers to an increase in red blood cell mass, noted on laboratory evaluation as increased hemoglobin and hematocrit levels. Polycythemia vera is a subtype of polycythemia and is associated with the overproduction of all 3 cell lines.

What is JAK2 gene?

Listen to pronunciation. (… jeen) A gene that makes a protein that sends signals in cells to promote cell growth and helps control the number of red blood cells, white blood cells, and platelets that are made in the bone marrow.

What is chronic myeloproliferative disorder?

Clinical Information. A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages.

What is the table of neoplasms used for?

The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.

What is the code for myelofibrosis?

Codes. D45 Polycythemia vera.

What is a chronic myeloproliferative neoplasm?

A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. Excessive proliferation of the myeloid lineage is observed as well. The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass. The cause is unknown.

What is a myeloproliferative disorder?

A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia.

What is a type 1 exclude note?

A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as D45. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition. familial polycythemia (.

What are the most common nonhematologic adverse reactions in myelofibrosis?

In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections and edema. Dose modifications may be required when administering Jakafi ...

Does Jakafi cause anemia?

Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated

Does Jakafi need to be modified?

Dose modifications may be required when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.

What does rhogam mean in pregnancy?

In pregnant women, the results indicate whether she is Rh positive or negative and whether she may be a candidate for receiving Rh immune globulin (RhoGAM) to prevent her from potentially developing antibodies against fetal red blood cells. Note: Some pregnant women might express weak D antigen.

What is blood typing?

Blood typing is a screening test to determine blood groups and Rh antigen for blood transfusion and pregnancy. The four blood groups A, B, O, and AB are determined by the presence of antigens A and B or their absence (O) on a patient's red blood cells.

What mutation is detected in PCR?

The quantitative real-time PCR assay detects V617F mutation (c.1849 G>T) observed in approximately 95% polycythemia vera (pv), 55% essential thrombocythemia (ET), and 55% primary myelofibrosis (PMF). It is also infrequently present (3% to 5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia, and other atypical chronic myeloid disorders. The results should be interpreted in the context of all clinical and laboratory findings. No therapeutic action should be taken based solely on these results.

Does the JAK2V617F test detect other mutations?

This assay detects only the JAK2V617F point mutation. Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Primary Site (s)

Primary site must be bone marrow (C421). Blood and bone marrow are the primary sites of involvement.

Abstractor Notes

Treatment is used for control, not cure. The patient has phlebotomy (removal of blood, usually a pint every other day) until the hematocrit reaches a normal level. Then blood is removed every few months as needed. Aspirin was previously documented as treatment for MPN, NOS. This was found to be incorrect.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Definition

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by increased red blood cell ( RBC) production independent of the mechanisms that normally regular erythropoiesis.

Sources

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.